NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies...
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Ovid Therapeutics is ramping up its patent fight with Marinus Pharmaceuticals.
Ovid Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide...
Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash...
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to OvidOvid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash...
Ovid Therapeutics has sold off part of the royalty rights to its Takeda-partnered seizure med in order to fund its operations into 2026.